Our latest
News
Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance
Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales
Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio
Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio®
Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024
Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances
Mauna Kea Technologies Reports New Evidence Highly Supportive of the Use of Cellvizio for Diagnosing Pancreatic Cysts Presented at DDW 2024
Mauna Kea Technologies announces results of its Combined General Meeting of June 6, 2024
Mauna Kea Technologies Announces Joint Venture in China Obtained Class II Medical Device Business License
Mauna Kea Technologies Winner of “Best New Technology Solution – Oncology” MedTech Breakthrough Award
Mauna Kea Technologies Announces the Availability of Preparatory Documents for the Combined General Meeting of June 6, 2024 and the Instructions for Participation